Inhibrx Biosciences, Inc. Insider Buying: Mark Lappe Adds Stake

A Form 4 filed with the SEC shows Mark Lappe, CEO at Inhibrx Biosciences, Inc. (INBX), purchased 25,000 shares of company stock on 2026-09-08.

The transaction was executed at a price of $105.82 per share, for a total value of approximately $2.65 million.

Under SEC rules, corporate insiders — officers, directors, and holders of more than 10% of a company's shares — are required to report changes in their ownership within two business days of the transaction via Form 4.

Insider buying is sometimes viewed by investors as a signal of confidence in a company's prospects, though a single transaction does not necessarily indicate a broader trend.